Treatment options for patients with brain metastatic disease in HER2-positive breast cancer

Bibliographic Details
Published in:	Indian Journal of Medical and Paediatric Oncology
Main Author:	Manikandan Dhanushkodi
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2020-01-01
Online Access:	http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=5;spage=735;epage=737;aulast=Dhanushkodi

Similar Items

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options
by: Sarah K Premji, et al.
Published: (2024-02-01)

Trastuzumab: A milestone in human epidermal growth factor receptor 2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2020-01-01)

Neratinib for HER2-positive breast cancer with an overlooked option
by: Liting Guo, et al.
Published: (2023-10-01)

Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
by: M. Calamac, et al.
Published: (2021-04-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
by: Zihong Wu, et al.
Published: (2023-03-01)

Multilineal treatment strategy of HER2-positive metastatic breast cancer (clinical case)
by: A. F. Nasretdinov, et al.
Published: (2021-06-01)

Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: Focus on Capivasertib
by: Julia Landin, et al.
Published: (2025-10-01)

HER-2-positive metastatic breast cancer: new possibilities for therapy
by: E. V. Artamonova, et al.
Published: (2014-07-01)

Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series
by: Reshma Mahtani, et al.
Published: (2024-08-01)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
by: Xiaoping Ma, et al.
Published: (2022-12-01)

The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer
by: Larissa Russo-Vorms, et al.
Published: (2021-10-01)

Efficacy and safety of pyrotinib in the treatment of HER2-positive liver metastatic advanced breast cancer
by: Yongxia Li, et al.
Published: (2025-04-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Male HER-2 positive metastatic breast cancer: A case report
by: Na Lin, et al.
Published: (2020-12-01)

Exploring the full potential of Pyrotinib in HER2-positive metastatic breast cancer
by: Wei-Zhen Tang, et al.
Published: (2025-08-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China
by: Xinzhao Wang MD, et al.
Published: (2021-08-01)

The prognostic significance of FOXP3 expression in patients with metastatic HER2-positive breast cancer
by: O.I. Vynnychenko, et al.
Published: (2024-12-01)

Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
by: Cong Xue, et al.
Published: (2022-12-01)

Real-world treatment patterns and outcomes among patients with HER2-positive unresectable or metastatic breast cancer in China
by: Jiajia Huang, et al.
Published: (2025-05-01)

Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
by: Natasha B. Hunter, et al.
Published: (2025-02-01)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
by: Mark Pegram, et al.
Published: (2023-08-01)

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
by: Naoki Niikura, et al.
Published: (2023-10-01)

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
by: G. A. Dashyan, et al.
Published: (2016-06-01)

The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options
by: Claudia von Arx, et al.
Published: (2024-12-01)

Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review
by: Michelle D. Hackshaw, et al.
Published: (2021-08-01)

Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer
by: Ana C. Garrido-Castro, et al.
Published: (2023-06-01)

Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: a multicenter real-world study
by: Jing Peng, et al.
Published: (2025-10-01)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
by: Angela Dalia Ricci, et al.
Published: (2021-11-01)

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
by: Wei Wang, et al.
Published: (2024-01-01)

Potential of afatinib in the treatment of patients with HER2-positive breast cancer
by: Geuna E, et al.
Published: (2012-08-01)

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
by: Selin Aktürk Esen, et al.
Published: (2022-09-01)

Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
by: Azzurra Irelli, et al.
Published: (2024-01-01)

CLINICAL CASE OF SUCCESFUL APPLICATION OF KADSYLA APPLICATION IN METASTATIC HER2 POSITIVE BREAST CANCER
by: D. D. Sakaeva
Published: (2017-11-01)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
by: Bin Shao, et al.
Published: (2022-08-01)

Brain Radiotherapy Combined with Targeted Therapy for HER2-Positive Breast Cancer Patients with Brain Metastases
by: Tang L, et al.
Published: (2024-07-01)